Published 14 hours ago • loading... • Updated 13 hours ago

Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation

On Wednesday, Nona Biosciences appointed Dr. Josh Xiao as Chief Scientific Officer. Xiao will lead the company's global scientific strategy and oversee the evolution of its technology platforms.
Dr. Xiao brings more than 25 years of experience in drug discovery to the role. Dr. Di Hong, Chief Executive Officer of Nona Biosciences, noted his extensive background in translational medicines will be instrumental to the company's growth.
"I am thrilled to join the Nona Biosciences team, and very excited to help strengthen and expand our technology platforms," said Dr. Josh Xiao. He will oversee H2L2 Harbour Mice and the Hu-mAtrIxTM AI-driven drug discovery platform.
Reporting directly to Dr. Di Hong, Dr. Xiao will lead global Project Leaders to enhance project execution. Based in China, he will establish a structured framework to deepen scientific insight into partner needs.
Prior to this, Dr. Xiao led scientific teams at Amgen and Takeda. He holds a Ph.D. in Biochemistry from Louisiana State University and completed postdoctoral training at Columbia University.

Insights by Ground AI

37 Articles

The Conway Daily Sun

+36 Reposted by 36 other sources

Center

Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation

CAMBRIDGE, Mass., May 6, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao as Chief Scientific Officer (CSO). Dr. Xiao will…

14 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year